the aid library

LIST OPTIONS

Filter

14445

Management of critical COVID-19: Acute hypoxaemic respiratory failure and COVID-19: Recognize ARDS
recommended

World Health Organization WHO (2022) C_WHO

WHO recommends prompt recognition of progressive acute hypoxaemic respiratory failure when a patient with respiratory distress is failing to respond to standard oxygen therapy and adequate preparation to provide advanced oxygen/ventilatory support. Hypoxaemic respiratory failure in ARDS commonly ... more

Vigilancia de anomalías congénitas

World Health Organization WHO (2022) C_WHO

manual de referencia rápida de anomalías congénitas e infecciones seleccionadas

External Link

Pakistan Crisis 2022
recommended

World Health Organization WHO (2022) C_WHO

WHO is responding as Pakistan is affected by massive monsoon rainfall and unprecedented levels of flooding and landslides. Damage to health infrastructure, shortages of health workers, and limited health supplies are disrupting health services. Significant public health threats include the spread of... more

Download (165)

View PDF (177)

Prevention of disability in Buruli ulcer

World Health Organization WHO WHOOMS (2006) C_WHO

Prevention of disability in Buruli ulcer through health education and self-care training

Download (107)

View PDF (140)

Capacité juridique et droit à la décision – Formation de base de QualiyRights de l‘OMS-Services sociaux et de santé mentale

World Health Organisation (WHO) (2022) C_WHO

Les modules de formation et d’orientation QualityRights ont été élaborés pour renforcer les connaissances, les compétences et la compréhension des principales parties prenantes sur la manière de promouvoir les droits des personnes en situation de handicap psychosocial, intellectuel ou cogni... more

Download (150)

View PDF (150)

Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy

World Health Organization WHO (2022) C_WHO

WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi... more

External Link

Trachoma

World Health Organization WHO (2020) C_WHO

WHO Fact sheets, questions and answers. Trachoma is a disease of the eye and the leading infectious cause of blindness worldwide.

External Link

Frequently Asked Questions on Chikungunya Fever

World Health Organization - Regional Office for South-East Asia WHO Regional Office for South-East Asia (2013) CC

Information on Chikungunya Fever

External Link

Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever -Revised and expanded edition

World Health Organization WHO Regional Office for South-East Asia WHO Regional Office for South-East Asia (2011) CC

Revised and expanded version of the Guidelines

External Link

Chikungunya fact sheet

World Health Organization WHO WHO (2022) CC

Chikungunya: WHO fact sheet on Chikungunya providing key facts and information on scope of the problem, who is at risk, prevention, WHO response.

Download (119)

View PDF (176)

Target product profile for a gambiense human African trypanosomiasis test to identify individuals to receive widened treatment

World Health Organization WHO (2022) C_WHO

The development of this target product profile (TPP) was led by the WHO Department of Control of Neglected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical Advisory Group (DTAG) was form... more

Download (142)

View PDF (164)

Target product profile for a point-of-care diagnostic test for dermal leishmaniases - Control of Neglected Tropical Diseases

World Health Organization WHO (2022) C_WHO

Localized cutaneous leishmaniasis and its evolving forms (diffuse cutaneous leishmaniasis, mucosal leishmaniasis and cutaneous leishmaniasis recidivans), together with the sequela of visceral leishmaniasis (post-kala-azar dermal leishmaniasis), account for about one million cases of dermal leishmani... more

Download (131)

View PDF (190)

Preparedness for cyclones, tropical storms, tornadoes, floods and earthquakes during the COVID-19 pandemic

World Health Organisation (WHO) (2023) C_WHO

The WHO health advisory provides guidance to countries on adapting all existing preparedness and response plans and procedures for natural hazards such as cyclones, tropical storms, tornadoes, floods, earthquakes and potential outbreaks of other diseases to their existing COVID-19 strategic prepared... more

External Link

Supporting countries in their foodborne trematode infections control efforts

World Health Organization WHO (2023) C_WHO

WHO promotes the inclusion of foodborne trematodiases among the targets of preventive chemotherapy interventions. With the aim of providing access to quality medicines, WHO has negotiated with Novartis Pharma AG whereby Novartis donates triclabendazole for the treatment of fascioliasis and paragonim... more

External Link

Foodborne trematode infections - arabic verison

World Health Organization WHO (2023) C_WHO

Website last accessed on 14.04.2023 Food-borne trematode infections are zoonotic, and their pathogens can be transmitted to humans only after the completion of a complex life cycle, some stages of which take place in the body of an intermediate animal host. The first intermediate hosts of all tr... more

Keeping the vector out: housing improvements for vector control and sustainable development

Kraef, C.; Röbbel, N. World Health Organization WHO (2017) C_WHO

Vector-borne diseases are responsible for 17% of the global burden of communicable diseases and more than 500 000 deaths annually. The ambitious global targets for the control of vector-borne diseases come in the context of the (re-)emergence of diseases, increasing resistances to insecticides and u... more

Download (107)

View PDF (119)

Audited Financial Statements for the year ended 31 December 2020

World Health Organization (WHO) World Health Organization (WHO) (2021) CC

WHO’s total revenue in 2020 was US$ 4299 million and total expenses were US$ 3561 million, resulting in a surplus of US$ 824 million, which includes finance revenue (e.g. interest and investment income) of US$ 86 million, representing increases of 38% and 15% in revenue and expenses respectively. ... more

Download (88)

View PDF (91)

Sustainable financing: feasibility of a replenishment mechanism, including options for consideration - Report by the Director-General

World Health Organization (WHO) World Health Organization (WHO) (2022) CC

The Seventy-fifth World Health Assembly through a decision on sustainable financing, adopted the recommendations of the Member States Working Group on Sustainable Financing, contained in Appendix 2 of the Working Group’s report to the Seventy-fifth World Health Assembly. As part of the recommendat... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (223)

View PDF (241)

Clinical management of diphtheria: guideline

World Health Organization WHO (2024) C_WHO

WHO has published the first-ever guidance on the clinical management of diphtheria. The only previously available guidance was an operational protocol. The new guidance followed the rigorous process for developing guidance at WHO. It addresses the use of Diphtheria Antitoxin (DAT) in the treatmen... more

Management of critical COVID-19: Acute hypoxaemic respiratory failure and COVID-19: Recognize ARDS recommended

Pakistan Crisis 2022 recommended

Management of critical COVID-19: Acute hypoxaemic respiratory failure and COVID-19: Recognize ARDS
recommended

Pakistan Crisis 2022
recommended